Primary antifungal prophylaxis in leukaemia patients

European Journal of Cancer, Supplement

Volumn 5, Issue 2, 2007, Pages 43-48

  Maertens, Johan A ^a   Frère, Pascale ^b   Lass Flörl, Cornelia ^c   Heinz, Werner ^d   Cornely, Oliver A ^e  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e Klinik I für Innere Medizin   (Germany)

Author keywords

Antifungal; Aspergillus; Candida; Leukaemia; Neutropenia; Prophylaxis; Stem cell transplantation

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; ECHINOCANDIN; FLUCONAZOLE; FLUDARABINE; ITRACONAZOLE; MICAFUNGIN; NYSTATIN; PLACEBO; POLYENE; POSACONAZOLE; PYRROLE; VORICONAZOLE;

AEROSOL; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG CAPSULE; DRUG FORMULATION; DRUG MEGADOSE; DRUG USE; EUROPE; HUMAN; LEUKEMIA; LIVER TOXICITY; MONOTHERAPY; MYCOSIS; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; STEM CELL TRANSPLANTATION; UNSPECIFIED SIDE EFFECT;

EID: 34547581786     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2007.06.006     Document Type: Article

References (40)

1. Viscoli C., Girmenia C., Marinus A., et al. Candidemia in cancer patients: a prospective multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of cancer (EORTC). Clin Infect Dis 28 (1999) 1071-1079
2. Lin S.J., Schranz J., and Teutsch S.M. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32 (2001) 358-366
3. von Eiff M., Roos N., Schulten R., et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 62 (1995) 341-347
4. Hope W.W., Walsh T.J., and Denning D.W. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 5 (2005) 609-622
5. Dykewicz C.A. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 33 (2001) 139-144
6. de Pauw B. Preventative use of antifungal drugs in patients treated for cancer. J Antimicrob Chemother 53 (2004) 130-132
7. Goodman J.L., Winston D.J., Greenfield R.A., et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New Engl J Med 326 (1992) 845-851
8. Slavin M.A., Osborne B., Adams R., et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized double blind study. J Infect Dis 171 (1995) 1545-1552
9. Rotstein C., Bow E.J., Laverdiere M., et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 28 (1999) 331-340
10. Schaffner A., and Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care cost in patients undergoing intensive chemotherapy for hematological neoplasias. J Infect Dis 172 (1995) 1035-1041
11. Winston D.J., Chandrasekar P.H., Lazarus H.M., et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized, placebo-controlled, double-blind, multicenter trial. Ann Intern Med 118 (1993) 495-503
12. Cornely O.A., Ullmann A.J., and Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with haematological malignancies. Blood 101 (2003) 3365-3372
13. Bow E.J., Laverdiere M., Lussier N., et al. Antifungal prophylaxis for severely neutropenic chemotherapy patients. A meta-analysis of randomized-controlled clinical trials. Cancer 94 (2002) 3230-3246
14. Marr K.A., Seidel K., Slavin M.A., et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 96 (2000) 2055-2061
15. Huijgens P.C., Simoons-Smit A.M., Van Loenen A.C., et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J Clin Pathol 52 (1999) 376-380
16. Nucci M., Biasoli I., Akiti T., et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 30 (2000) 300-305
17. Vreugdenhil G., Van Dijke B.J., Donnelly J.P., et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematological malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymph 11 (1993) 353-358
18. Menichetti F., Del Favero A., Martino P., et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis 28 (1999) 250-255
19. Morgenstern G.R., Prentice A.G., Prentice H.G., et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. Br J Haematol 105 (1999) 901-911
20. Harousseau J.-L., Dekker A.W., Stamatoullas-Bastard A., et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 44 (2000) 1887-1893
21. Boogaerts M., Maertens J., Van Hoof A., et al. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J Antimicrob Chemother 48 (2001) 97-103
22. Glasmacher A., Cornely O., Ullmann A.J., et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 57 (2006) 317-325
23. Glasmacher A., Prentice A., Gorschluter M., et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 21 (2003) 4615-4626
24. Winston D.J., Maziarz R.T., Chandrasekar P.H., et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomised trial. Ann Intern Med 138 (2003) 705-713
25. Marr K.A., Crippa F., Leisenring W., et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103 (2004) 1527-1533
26. Vardakas K.Z., Michalopoulos A., and Falagas M.E. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 131 (2005) 22-28
27. Marr K.A., Crippa F., Leisenring W., et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 103 (2004) 1557-1559
28. Glasmacher A., Hahn C., Molitor E., et al. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-β-cyclodextrin oral solution or coated-pellet capsules. Mycoses 42 (1999) 591-600
29. Schwartz S., Behre G., Heinemann V., et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: results of a prospective, randomized trial. Blood 93 (1999) 3654-3661
30. Rousey S.R., Russler S., Gottlieb M., et al. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. Am J Med 91 (1991) 484-492
31. Perfect J.R., Klotman M.E., Gilbert C.C., et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 165 (1992) 891-897
32. Tollemar J., Ringdén O., Andersson S., et al. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 12 (1993) 577-582
33. Kelsey S.M., Goldman J.M., McCann S., et al. Liposomal amphotericin B (Ambisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 23 (1999) 163-168
34. Timmers G.J., Zweegman S., Simoons-Smit A.M., et al. Amphotericin B colloidal dispersion (Amphocil) vs. fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplant 25 (2000) 879-884
35. van Burik J.A., Ratanatharathorn V., Stepan D.E., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39 (2004) 1407-1416
36. Cornely O, Maertens J, Winston D, et al. Posaconazole versus standard azole therapy for prophylaxis of invasive fungal infections among high-risk neutropenic patients: results of a randomized, multicenter trial. In: Abstracts of the 47th annual meeting of the American society of hematology, Atlanta, Georgia; 2005 [abstract 48-II].
37. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole versus fluconazole for prophylaxis of invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease: results of a multicenter trial. In: Abstracts of the 45th Interscience Conference on antimicrobial Agents and Chemotherapy, Washington, DC. American Society for Microbiology, Washington (DC, USA); 2005. p. 418 [abstract M-716].
38. Marr K.A., Seidel K., White T.C., et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 181 (2000) 309-316
39. Lionakis M.S., Lewis R.E., Torres H.A., et al. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis 52 (2005) 15-20
40. Trifilio S., Verma A., and Mehta J. Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant 33 (2004) 735-739